Possibia

1839981

Last Update Posted: 2018-12-27

Recruiting has ended

All Genders

accepted

18 Years +

10 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer. Drugs used in chemotherapy, such as 6,8-bis(benzylthio)octanoic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PRIMARY OBJECTIVES:

I. To determine initial estimates of overall survival (OS).

SECONDARY OBJECTIVES:

I. To determine response rate. II. To determine progression free survival (PFS).

OUTLINE:

Patients receive 6,8-bis(benzylthio)octanoic acid intravenously (IV) over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Eligibility

Relevant conditions:

Acinar Cell Adenocarcinoma of the Pancreas

Duct Cell Adenocarcinoma of the Pancreas

Recurrent Pancreatic Cancer

Stage III Pancreatic Cancer

Stage IV Pancreatic Cancer

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov